- Home
- MLCO vs TLX Comparison
MLCO vs TLX Comparison
Compare MLCO & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLCO
- TLX
- Stock Information
- Founded
- MLCO 2004
- TLX 2015
- Country
- MLCO Hong Kong
- TLX Australia
- Employees
- MLCO N/A
- TLX N/A
- Industry
- MLCO Hotels/Resorts
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- MLCO Consumer Discretionary
- TLX Health Care
- Exchange
- MLCO Nasdaq
- TLX Nasdaq
- Market Cap
- MLCO 3.7B
- TLX 3.6B
- IPO Year
- MLCO 2006
- TLX N/A
- Fundamental
- Price
- MLCO $8.41
- TLX $10.84
- Analyst Decision
- MLCO Buy
- TLX Strong Buy
- Analyst Count
- MLCO 6
- TLX 4
- Target Price
- MLCO $9.78
- TLX $21.00
- AVG Volume (30 Days)
- MLCO 2.9M
- TLX 118.4K
- Earning Date
- MLCO 10-31-2025
- TLX 01-01-0001
- Dividend Yield
- MLCO N/A
- TLX N/A
- EPS Growth
- MLCO N/A
- TLX N/A
- EPS
- MLCO 0.14
- TLX 0.04
- Revenue
- MLCO $4,926,670,000.00
- TLX $664,225,558.00
- Revenue This Year
- MLCO $12.85
- TLX N/A
- Revenue Next Year
- MLCO $3.61
- TLX N/A
- P/E Ratio
- MLCO $60.97
- TLX $335.52
- Revenue Growth
- MLCO 12.41
- TLX 55.35
- 52 Week Low
- MLCO $4.55
- TLX $8.93
- 52 Week High
- MLCO $10.15
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- MLCO 47.40
- TLX 56.21
- Support Level
- MLCO $7.81
- TLX $10.74
- Resistance Level
- MLCO $8.56
- TLX $11.00
- Average True Range (ATR)
- MLCO 0.40
- TLX 0.26
- MACD
- MLCO 0.06
- TLX 0.09
- Stochastic Oscillator
- MLCO 73.00
- TLX 75.05
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts and Entertainment Ltd is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao with the rest largely from the Philippines as of 2024.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.